Cardiol Therapeutics Liabilities 2024

Cardiol Therapeutics Aktienanalyse

What does Cardiol Therapeutics do?

Cardiol Therapeutics Inc is an international biopharmaceutical company specializing in the development of innovative therapies for the treatment of heart diseases. The company was founded in 2006 in Canada and has since built a broad portfolio of products and technologies to improve the treatment of heart diseases. The company's business model is based on research and development of innovative therapies that aim to provide patients with more effective treatments for heart diseases. They collaborate closely with renowned research institutions and clinics worldwide to develop a wide range of innovative treatment options. The company has also specialized in the study of cannabinoids for the treatment of heart diseases, focusing on the development of medications tailored to the needs of patients with heart diseases. They have developed CardiolRx, a patented technology based on cannabinoids, which has shown promising results in clinical studies for the treatment of severe heart diseases such as heart failure and myocarditis. Overall, Cardiol Therapeutics Inc is a biopharmaceutical company dedicated to developing therapies for the treatment of heart diseases, with a focus on collaboration, innovative products, and the potential to significantly improve patient care. Cardiol Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Cardiol Therapeutics's Liabilities

Cardiol Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cardiol Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cardiol Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cardiol Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cardiol Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cardiol Therapeutics stock

What is the level of liabilities of Cardiol Therapeutics this year?

Cardiol Therapeutics has a debt balance of 8.45 M CAD this year.

What were the liabilities of Cardiol Therapeutics compared to the previous year?

The liabilities of Cardiol Therapeutics have increased by -14% dropped compared to the previous year.

What are the consequences of high debt for investors of Cardiol Therapeutics?

High liabilities can pose a risk for investors of Cardiol Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Cardiol Therapeutics?

Low liabilities mean that Cardiol Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Cardiol Therapeutics affect the company?

An increase in liabilities of Cardiol Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Cardiol Therapeutics affect the company?

A decrease in the liabilities of Cardiol Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Cardiol Therapeutics?

Some factors that can influence the liabilities of Cardiol Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Cardiol Therapeutics so important for investors?

The liabilities of Cardiol Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Cardiol Therapeutics take to modify the liabilities?

To change its liabilities, Cardiol Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Cardiol Therapeutics pay?

Over the past 12 months, Cardiol Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cardiol Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Cardiol Therapeutics?

The current dividend yield of Cardiol Therapeutics is .

When does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cardiol Therapeutics?

Cardiol Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cardiol Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cardiol Therapeutics located?

Cardiol Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cardiol Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cardiol Therapeutics from 10/2/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Cardiol Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Cardiol Therapeutics in the year 2023?

In the year 2023, Cardiol Therapeutics distributed 0 CAD as dividends.

In which currency does Cardiol Therapeutics pay out the dividend?

The dividends of Cardiol Therapeutics are distributed in CAD.